Estimation of and clinical consensus on the meaningful motor progression threshold on MDS-UPDRS Part III
Open Access
- 14 January 2025
- journal article
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (1) , 97-110
Abstract
Background: To understand changes in the underlying progression of early Parkinson's disease, it is important to derive estimates of the threshold for meaningful motor progression on the MDS-UPDRS Part III in OFF medication state. Objective: To estimate this threshold using two approaches: anchor-based analyses, and clinical consensus via a modified Delphi panel. Methods: For the anchor-based analyses, data from a Phase II clinical trial were used. Mean and median MDS-UPDRS Part III change scores were calculated for those participants rated as ‘Minimally worse’ on the Clinical Global Impression of Improvement (using the first visit rated as ‘Minimally worse’ or worse, and at Weeks 24 and 52). Cumulative data up to Week 104 were used to assess the difference between motor progressors’ and non-progressors’ change scores on motor-related outcomes. For the modified Delphi panel, a panel of 13 expert clinicians received an online survey in two rounds and provided responses anonymously. Results: For the anchor-based analyses, estimates of meaningful change ranged from 4−6 points. Numerically worse change scores were identified on motor-related outcomes for participants who had experienced motor progression compared with those who had not. For the modified Delphi panel, consensus was reached in Round 2, with 92% agreeing that 5 points is suitable to define a clinically meaningful motor progression threshold. Conclusions: Results of the anchor-based analyses and modified Delphi panel were consistent, supporting a meaningful motor progression threshold of a worsening of 5 points on the MDS-UPDRS Part III (OFF medication state) in an early Parkinson's disease population.Keywords
Funding Information
- F. Hoffmann-La Roche
This publication has 30 references indexed in Scilit:
- Minimal Clinically Important Difference for UPDRS‐III in Daily PracticeMovement Disorders Clinical Practice, 2018
- Progression of MDS‐UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative CohortMovement Disorders Clinical Practice, 2017
- Determination of minimal clinically important change in early and advanced Parkinson's diseaseMovement Disorders, 2011
- Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD studyAnnals of Neurology, 2010
- The Clinically Important Difference on the Unified Parkinson's Disease Rating ScaleArchives of Neurology, 2010
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing resultsMovement Disorders, 2008
- Minimal clinically important change on the unified Parkinson's disease rating scaleMovement Disorders, 2006
- Defining the Bobath concept using the Delphi techniquePhysiotherapy Research International, 2006
- A Controlled Trial of Rasagiline in Early Parkinson DiseaseArchives of Neurology, 2002
- Pramipexole vs Levodopa as Initial Treatment for Parkinson DiseaseJAMA, 2000